PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Dupilumab - Atopic dermatitis

PAD Profile : Dupilumab - Atopic dermatitis

Keywords :
Dermatology, immunomodulator,
Brand Names Include :
Dupixent

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
BNF NICE SPC
NFD1
SA
ICB
BlueTeq
NICE
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated Atopic Dermatitis treatment pathway

05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network recommends dupilumab as a treatment option for treating moderate to severe atopic dermatitis in line with NICE TA534 (August 2018).


Dupilumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians)


Dupilumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More